We've got a new pick for you that you may have heard of at some time in the past! It's a very popular OTC play that has made a lot of people a lot of money!
At the beginning of this year this play was over 300% higher than the current price and we believe there is certainly potential for another big multiday run in the future.
Our new pick is CBIS - Cannabis Science
If you were following the markets at the beginning of this year you know that anything involving the marijuana industry was absolutely booming.
CBIS was one of the favorites of many and still seems to have a great following as it remains pretty liquid to this day even after the buzz has died down.
In early February we saw nearly .30c from CBIS. WE are now sitting around .07c and although I don't think CBIS is the type of play to see huge gains in a single day, I believe the potential for a longer term swing trade is huge here.
Of course we are speculating here but we believe at some point in the near future we could see some big break through's in the legalization of marijuana which could push CBIS back into rally mode.
CBIS is a CO, USA based company operating the medical marijuana sector.
CBIS takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Their initial focus is on skin cancers and neurological conditions.
The Company's products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.
CS-S/BCC1 is in preparation to enter phase I clinical trials within one to two years. This product is formulated for topical administration to be tested in phase I study, with an indication for skin cancer.
CS-TATI1 is in preclinical development with the indication for infectious disease. Consistent with data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2) which has potential applications in HIV and other infectious diseases.
In 2013, CBIS submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety.
The first formulation in the series of neurobehavioral disorder-targeted products is the pre-clinical development and use of the invention in food products through a licensing agreement with partner company, ENDOCAN Corporation, Inc. And Cannabis Science will move forward at the same time with pharmaceutical grade development.
Take a look at the chart below and you can see the consolidation CBIS is seeing down in this range.
